SPONSOR
Genentech, Inc.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2
Conditions studied: Early Breast CancerGeographic AtrophyGeographic Atrophy Secondary to Age-Related Macular Degeneration
Genentech, Inc. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Early Breast Cancer, Geographic Atrophy, Geographic Atrophy Secondary to Age-Related Macular Degeneration.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Genentech, Inc.
How many clinical trials has Genentech, Inc. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Genentech, Inc., of which 3 are actively recruiting participants. These trials cover conditions including Early Breast Cancer, Geographic Atrophy, Geographic Atrophy Secondary to Age-Related Macular Degeneration. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Genentech, Inc. research focus on?
Genentech, Inc. clinical trials span Early Breast Cancer, Geographic Atrophy, Geographic Atrophy Secondary to Age-Related Macular Degeneration. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Genentech, Inc. clinical trial?
To participate in a Genentech, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Genentech, Inc. trials with current recruitment status updated daily.
Clinical Trials by Genentech, Inc.
NCT07541079 Phase 3
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Early Breast Cancer
NCT05626114 Phase 2
Recruiting
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Geographic Atrophy
NCT07851259 Phase 2
Recruiting
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic Atrophy Secondary to Age-Related Macular Degeneration
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology